Sponsor Overview
Explore verified public information about Celldex Therapeutics's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 3 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“In very specific circumstances, Celldex may provide access to our investigational products to patients with life-threatening diseases who have exhausted other treatment options and where there is a reasonable expectation of benefit over risk as defined in our Compassionate Use or Expanded Access Program.”
Past EAPs on ClinicalTrials.gov
Score contribution: 40 — 2 supporting sources.
Conditions: Recurrent GBM
Conditions: Metastatic gpNMB Expressing Triple Negative Breast Cancer
Reagan-Udall Foundation Insights
Available Therapies via Single-Patient EA None Disease/Category-Specific EA Policies/Criteria https://celldex.com/docs/Compassionate_Use_Policy_MAY2018.pdf
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.